Possible explanations for this finding include that VCAM-1 may be a marker of progression independent of ILD and PAH disease manifestations, or that VCAM-1 may predict progression prior to these manifestations which, when established, progress in association with other biomarkers. Here, VCAM1 is linked to interstitial lung disease.